vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.

FORRESTER RESEARCH, INC. is the larger business by last-quarter revenue ($101.1M vs $77.6M, roughly 1.3× Bioceres Crop Solutions Corp.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -33.5%, a 23.9% gap on every dollar of revenue. On growth, FORRESTER RESEARCH, INC. posted the faster year-over-year revenue change (-6.5% vs -16.8%). Over the past eight quarters, FORRESTER RESEARCH, INC.'s revenue compounded faster (0.5% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.

BIOX vs FORR — Head-to-Head

Bigger by revenue
FORR
FORR
1.3× larger
FORR
$101.1M
$77.6M
BIOX
Growing faster (revenue YoY)
FORR
FORR
+10.4% gap
FORR
-6.5%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
23.9% more per $
BIOX
-9.6%
-33.5%
FORR
Faster 2-yr revenue CAGR
FORR
FORR
Annualised
FORR
0.5%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
FORR
FORR
Revenue
$77.6M
$101.1M
Net Profit
$-7.4M
$-33.9M
Gross Margin
46.8%
56.7%
Operating Margin
9.3%
-36.6%
Net Margin
-9.6%
-33.5%
Revenue YoY
-16.8%
-6.5%
Net Profit YoY
-20.2%
-7941.4%
EPS (diluted)
$-0.12
$-1.75

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
FORR
FORR
Q4 25
$101.1M
Q3 25
$77.6M
$94.3M
Q2 25
$111.7M
Q1 25
$60.6M
$89.9M
Q4 24
$98.8M
$108.0M
Q3 24
$93.3M
$102.5M
Q2 24
$121.8M
Q1 24
$84.0M
$100.1M
Net Profit
BIOX
BIOX
FORR
FORR
Q4 25
$-33.9M
Q3 25
$-7.4M
$-2.1M
Q2 25
$3.9M
Q1 25
$-1.6M
$-87.3M
Q4 24
$605.2K
$432.0K
Q3 24
$-6.2M
$-5.8M
Q2 24
$6.3M
Q1 24
$9.8M
$-6.7M
Gross Margin
BIOX
BIOX
FORR
FORR
Q4 25
56.7%
Q3 25
46.8%
60.0%
Q2 25
55.5%
Q1 25
39.4%
55.9%
Q4 24
42.0%
58.8%
Q3 24
40.2%
60.5%
Q2 24
57.3%
Q1 24
50.8%
54.9%
Operating Margin
BIOX
BIOX
FORR
FORR
Q4 25
-36.6%
Q3 25
9.3%
4.7%
Q2 25
6.2%
Q1 25
1.5%
-97.5%
Q4 24
14.5%
-0.5%
Q3 24
2.5%
-0.7%
Q2 24
9.3%
Q1 24
15.7%
-9.3%
Net Margin
BIOX
BIOX
FORR
FORR
Q4 25
-33.5%
Q3 25
-9.6%
-2.3%
Q2 25
3.5%
Q1 25
-2.6%
-97.1%
Q4 24
0.6%
0.4%
Q3 24
-6.6%
-5.7%
Q2 24
5.2%
Q1 24
11.6%
-6.7%
EPS (diluted)
BIOX
BIOX
FORR
FORR
Q4 25
$-1.75
Q3 25
$-0.12
$-0.11
Q2 25
$0.20
Q1 25
$-0.02
$-4.62
Q4 24
$0.00
$0.02
Q3 24
$-0.10
$-0.30
Q2 24
$0.33
Q1 24
$0.14
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
FORR
FORR
Cash + ST InvestmentsLiquidity on hand
$15.5M
$63.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$126.5M
Total Assets
$734.9M
$404.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
FORR
FORR
Q4 25
$63.3M
Q3 25
$15.5M
$65.1M
Q2 25
$67.8M
Q1 25
$38.5M
$75.6M
Q4 24
$29.2M
$56.1M
Q3 24
$32.3M
$62.8M
Q2 24
$58.9M
Q1 24
$16.4M
$61.4M
Stockholders' Equity
BIOX
BIOX
FORR
FORR
Q4 25
$126.5M
Q3 25
$288.3M
$157.7M
Q2 25
$159.5M
Q1 25
$345.0M
$147.4M
Q4 24
$346.3M
$229.5M
Q3 24
$346.0M
$234.3M
Q2 24
$237.1M
Q1 24
$348.5M
$230.9M
Total Assets
BIOX
BIOX
FORR
FORR
Q4 25
$404.0M
Q3 25
$734.9M
$414.2M
Q2 25
$436.0M
Q1 25
$798.2M
$439.8M
Q4 24
$835.2M
$503.9M
Q3 24
$827.3M
$505.3M
Q2 24
$524.2M
Q1 24
$836.1M
$555.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
FORR
FORR
Operating Cash FlowLast quarter
$14.4M
$-3.2M
Free Cash FlowOCF − Capex
$-4.3M
FCF MarginFCF / Revenue
-4.2%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$18.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
FORR
FORR
Q4 25
$-3.2M
Q3 25
$14.4M
$1.2M
Q2 25
$-3.6M
Q1 25
$23.3M
$26.7M
Q4 24
$-5.4M
$-1.8M
Q3 24
$5.2M
$264.0K
Q2 24
$-2.9M
Q1 24
$-17.4M
$611.0K
Free Cash Flow
BIOX
BIOX
FORR
FORR
Q4 25
$-4.3M
Q3 25
$524.0K
Q2 25
$-4.2M
Q1 25
$26.1M
Q4 24
$-2.5M
Q3 24
$-223.0K
Q2 24
$-3.7M
Q1 24
$-815.0K
FCF Margin
BIOX
BIOX
FORR
FORR
Q4 25
-4.2%
Q3 25
0.6%
Q2 25
-3.8%
Q1 25
29.0%
Q4 24
-2.3%
Q3 24
-0.2%
Q2 24
-3.1%
Q1 24
-0.8%
Capex Intensity
BIOX
BIOX
FORR
FORR
Q4 25
1.1%
Q3 25
0.7%
Q2 25
0.5%
Q1 25
0.7%
Q4 24
0.6%
Q3 24
0.5%
Q2 24
0.7%
Q1 24
1.4%
Cash Conversion
BIOX
BIOX
FORR
FORR
Q4 25
Q3 25
Q2 25
-0.93×
Q1 25
Q4 24
-8.85×
-4.24×
Q3 24
Q2 24
-0.46×
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

FORR
FORR

Research Segment$82.2M81%
Consulting Segment$16.2M16%
Billable Expenses$1.5M2%
Professional Services$1.4M1%

Related Comparisons